KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.

Mohamad Mohty, Gerard Socié, Jeff Szer, Dietger Niederwieser, Jason Butler, Eva Wagner-Drouet, Reuven Or, Tsila Rovenvald-Zuckerman, Sinem Civriz Bozdag, Edouard Forcade, Giovanni Grillo, Nicolaus Kröger, Friedrich Stölzel, Domenico Russo, Jaime Sanz, Rajendra Sarkar, Tommaso Stefanelli, Celine Wilke, Robert Zeiser, Nikolas von Bubnoff

J Clin Oncol 43(34) 3639-3645

PMID41092247
PMCIDPMC12634147
DOI10.1200/JCO-25-00809
发表日期2025-10-15
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Approximately 30%-50% of patients develop acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (Allo-HCT), representing a major limitation of this treatment. Although corticosteroids remain the standard first-line therapy for aGVHD, up to 50% of patients become steroid-refractory (SR). REACH2 is a phase III study of ruxolitinib versus best available therapy (BAT) in patients age 12 years and older with SR-aGVHD after Allo-HCT. We present the final efficacy and safety outcomes from REACH2 after 24 months of treatment. Cumulative median (range) duration of response was 167 (22-677) days with ruxolitinib and 106 (10-526) days with BAT. Median overall survival and event-free survival were 10.7 and 8.3 months for ruxolitinib, compared with 5.8 and 4.2 months, respectively, with BAT. Median failure-free survival was significantly longer with ruxolitinib than with BAT (4.86 v 1.02 months, P < .001). Similar numbers of nonrelapse mortality events were observed with ruxolitinib and BAT (72 v 71), and malignancy relapse/progression events remained low across both groups. Numerically higher chronic GVHD rates were noted with ruxolitinib than with BAT from 12 months; however, 95% confidence intervals overlapped. Safety observations were consistent with the primary analysis results. Ruxolitinib provided efficacy advantages over BAT in patients with SR-aGVHD over 24 months.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

FIG 2.

FIG 2. Efficacy outcomes (full analysis set). Kaplan-Meier curves for ruxolitinib and BAT for (A) OS, (B) EFS, and (C) FFS. OS was defined as the time from date of random assignment to the date of death due to any cause. EFS was defined as the time from date of random assignment to the date of hematologic disease relapse/progression, graft failure, or death due to any cause. FFS was defined as the time from the date of random assignment to the date of hematologic disease relapse/progression, nonrelapse mortality, or addition of new systemic aGVHD treatment. aGVHD, acute graft-versus-host disease; BAT, best available therapy; EFS, event-free survival; FFS, failure-free survival; HR, hazard ratio; KM, Kaplan-Meier, N, number of patients in a group; n, number of patients with a response; OS, overall survival.

A

OS

FIG 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 2:extreme upward reversal
查看结果
B

EFS

FIG 2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
C

FFS

FIG 2. · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:extreme upward reversal曲线 2:extreme upward reversal
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. CONSORT diagram and patient disposition. a One patient completed screening but was not randomly assigned due to not signing the informed consent form (protocol deviation). BAT, best available therapy.
非 KM Figure